论文部分内容阅读
目的：探索国人应用施太可（索他洛尔）治疗心律失常的疗效和合适剂量．方法：对５３例非心肌梗塞的心律失常患者采用施太可治疗，分别予不同剂量（４０～２４０ｍｇ／ｄ），观察疗效及不良反应，用临床及动态心电图进行评定．结果：（１）全部５３例患者应用施太可治疗后，总有效３９例，总有效率达７３．５８％．（２）３９例有效病例平均剂量为 ９３．５７ｍｇ／ｄ．（３）应用小剂量施太可后ＱＴｃ延长及心率减慢均有显著差异，但对血压下降无显著性差异．（４）共发生各种不良反应９例，其中窦缓２例，头晕４例，胸闷、乏力３例，无１例发生尖端扭转型室速．所有不良反应经减量后均达到改善，亦不影响疗效．结论：本组资料显示施太可治疗室性及室上性心律失常疗效较好，且所用的平均剂量要小于国内外报道，引起不良反应轻微，是临床上较好的抗心律失常药物．
OBJECTIVE: To explore the curative effect and appropriate dose of Chinese people for the treatment of arrhythmia with Strychnos (Sotalol). Methods: Fifty-three patients with arrhythmia without myocardial infarction were treated with STAP. The patients were treated with 40 ~ 240mg / d of different doses (40 ~ 240mg / d) respectively. The curative effect and adverse reactions were observed and evaluated by clinical and dynamic electrocardiogram. Results: (1) All 53 patients were treated with Shi Taike, the total effective in 39 cases, the total effective rate was 73.58%. (2) The average effective dose of 39 cases was 93.57mg / d. (3) There was a significant difference in QTc prolongation and heart rate slowing after application of low-dose STAP, but there was no significant difference in blood pressure drop. (4) A total of 9 cases of various adverse reactions occurred, of which 2 cases of sinus delay, 4 cases of dizziness, chest tightness, fatigue in 3 cases, no case of torsades de pointes occurred in 1 case. All adverse reactions have been reduced after the reduction, it does not affect the efficacy. Conclusion: The data in this group show that STAP can treat ventricular and supraventricular arrhythmias well, and the average dose used is less than that reported at home and abroad, causing minor adverse reactions and is a clinically good antiarrhythmic drug.